# Exelixis (EXEL) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/EXEL
## Company Profile
- Ticker: EXEL
- Exchange: NASDAQ
- Sector: Small Molecule Drugs
- Location: United States
- Tags: Small Molecule Drugs, Oncology
## Stock Data
- Close: 50.38 USD
- Market cap: 12200775728.82 USD
- Last updated: 2026-08-12
## Business Overview
### Commercial Oncology Company
Exelixis develops and commercializes therapies for genitourinary and gastrointestinal cancers. Revenue from its established cabozantinib franchise funds a broad effort to create additional oncology products and combinations.
### Cabozantinib Franchise
Cabozantinib is the company’s principal commercial asset and is marketed in the United States under the CABOMETYX brand across multiple tumor types. The franchise gives Exelixis an established commercial and clinical-development infrastructure in renal, liver and thyroid cancers.
### Zanzalintinib Franchise
Zanzalintinib is a next-generation tyrosine kinase inhibitor being studied in numerous pivotal and signal-seeking trials. The program includes combinations with atezolizumab, WELIREG and chemotherapy across colorectal, renal, lung, prostate and other cancers.
### Colorectal Cancer Registration
An NDA is under FDA review for zanzalintinib plus atezolizumab in previously treated metastatic colorectal cancer. The filing is supported by the Phase 3 STELLAR-303 trial, which demonstrated an overall-survival benefit versus regorafenib in the intent-to-treat population.
### Broad Clinical Expansion
The portfolio includes the Phase 3 STELLAR-304, STELLAR-311, STELLAR-316 and LITESPARK-034 studies, as well as Phase 2 programs in recurrent meningioma and planned work in lung cancer. This breadth is intended to establish zanzalintinib as a second major Exelixis franchise.
## Why The Stock Is Moving

As of Aug 12, 2026, EXEL closed down 1.85% at $50.38. No new same-company headline was identified in the current news window.

## Future Catalysts

- Final STELLAR-303 overall-survival analysis in patients without liver metastases expected in mid-2026, subject to event timing.
- Initiation of the Phase 3 STELLAR-316 trial expected in mid-2026.
- Topline results from the Phase 3 STELLAR-304 trial expected in the second half of 2026.
- FDA action on the zanzalintinib-plus-atezolizumab NDA expected by December 3, 2026.

## Recent News
- 2026-08-05 20:05 EST — [Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/EXEL/exelixis-announces-second-quarter-2026-financial-results-and-provides-corporate--778a8828) — Source: Exelixis
- 2026-07-22 20:30 EST — [Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026](https://biopharmsignal.com/news/EXEL/exelixis-to-release-second-quarter-2026-financial-results-on-wednesday-august-5--57b00d9c) — Source: Exelixis
- 2026-06-22 12:00 EST — [Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer](https://biopharmsignal.com/news/EXEL/exelixis-provides-update-on-the-phase-3-stellar-303-trial-evaluating-zanzalintin-de926b13) — Source: Exelixis
- 2026-05-30 14:00 EST — [Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026](https://biopharmsignal.com/news/EXEL/exelixis-announces-results-from-subgroup-analysis-of-phase-3-cabinet-pivotal-trial-evaluating-cabometyxr-cabozantinib-in-non-functional-and-functional-neuroendocrine-tumors-at-asco-2026) — Source: Exelixis
- 2026-05-27 20:05 EST — [Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June](https://biopharmsignal.com/news/EXEL/exelixis-to-webcast-fireside-chats-as-part-of-upcoming-investor-conferences-in-june) — Source: Exelixis